课题基金 / 基金详情

Interdepartmental Neuroscience Center

Interdepartmental Neuroscience Center
跨部门神经科学中心
批准号:
8995232
负责人:
XANDRA OWENS BREAKEFIELD
金额:
$69.6万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-05-01 至 2018-11-30

项目摘要

项目成果

XANDRA OWENS BREAKEFIELD的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):这个神经科学中心核心设施,由博士指导。Xandra Breakefield和Bakhos Tannous将成为一个独特的机构资源,将我们的神经科学教师聚集在一起,并通过强大的协同新技术加强他们对神经系统疾病的研究。这三个新提议的核心是真正的最先进的。成像核心(由dr。(Brad Hyman和Marian DiFiglia)将包括阵列断层扫描,透射电子显微镜和体内多光子成像详细的大脑结构。微流体核心(由博士指导。Daniel Irimia和Mehmet Toner将提供专门的微流体设备和专业知识,用于细胞和细胞器分离分析,以及细胞迁移和轴突引导的高精度实时成像。矢量核心(由dr。Bakhos Tannous和Xandra Breakefield)将为所有项目产生各种病毒载体,并随着该领域的进展继续扩大其储备,目前包括10种血清型腺相关病毒(AAV)载体和缺乏包衣的狂犬病毒。监督该项目的行政机构将包括P30主任/联席主任和核心主任/联席主任,以监督正在进行的活动并与用户进行交互;一个指导委员会,每年审查业务程序和活动报告,并就优先事项和核心有效性问题提供咨询意见;成立顾问委员会,就科技更新及管理事宜提供意见;所有这些服务都将免费提供给ninds资助的神经科学研究人员,并将有助于创造一个非常有活力的互动环境,让想法变成现实。这组神经科学研究人员包括该领域的国际领导者,以及初级和中级研究人员,他们的主要工作重点是神经系统疾病的研究,并在该领域做出了许多重大贡献。我们的研究涵盖了广泛的由中风、损伤、脑肿瘤和癫痫引起的神经系统疾病,以及神经退行性疾病,包括阿尔茨海默病、帕金森病和亨廷顿病,以及儿科疾病,如早发性肌张力障碍、家族性自主神经障碍、遗传性感觉和自主神经病变以及肾上腺脑白质营养不良。我们对这个PSO核心设施的愿景是实现对疾病发病机制的更深层次的理解,并通过提供能够实现大脑结构高分辨率的技术来发现缓解疾病的方法。
英文摘要
DESCRIPTION (provided by applicant): This Neuroscience Center Core Facility, directed by Drs. Xandra Breakefield and Bakhos Tannous will be an institutionally unique resource which will bring our neuroscience faculty together and enhance their research on neurologic disorders through powerful, synergistic new technologies. The three new proposed cores are truly state-of-the-art. The Imaging Core (directed by Drs. Brad Hyman and Marian DiFiglia) will include array tomography, transmission electron microscopy and in vivo multiphoton imaging of detailed brain structure. The Microfluidics Core (directed by Drs. Daniel Irimia and Mehmet Toner) will provide specialized microfluidic devices and expertise in analysis for separation of cells and cell organelles, and high precision, real-time imaging of cell migration and axon guidance. The Vector Core (directed by Drs. Bakhos Tannous and Xandra Breakefield) will generate a variety of viral vectors for all projects and continue to expand its repertoire with advances in this field now including 10 serotypes of adeno-associated virus (AAV) vectors and coat-deficient rabies virus. The administration organization overseeing this program will include the P30 Director/Co-Director and Core Directors/Co-Directors to monitor ongoing activities and to interface with users; a Steering Committee to review operating procedures and activity reports on an annual basis, and to advise on prioritization issues and core effectiveness; an Advisory Board to offer advice on technology updates and management issues; and an Administrative Core which will logistically support the program with a dedicated senior grants manager All these services will be offered free-of-charge to the NINDS-funded neuroscience investigators at our institution and will serve to create a very dynamic, interactive environment where ideas become reality. This group of neuroscience investigators includes international leaders in the field, as well as junior and mid-level investigators for whom research on neurologic disorders is the main focus of their work and who have made many major contributions in the field. Our research covers a broad range of neurologic disorders due to stroke, injury, brain tumors and seizures, as well as neurodegenerative diseases including Alzheimer's disease, Parkinson's disease and Huntington's disease, and pediatric disorders, such as early onset dystonia, familial dysautonomia, hereditary sensory and autonomic neuropathy and adrenoleukodystrophy. Our vision for this PSO Core Facility is to achieve a deeper level of understanding of disease pathogenesis and to discover means of alleviation by providing technologies which can achieve high resolution of brain structure.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Immuno-Cell Therapy for Brain Tumors
  • 批准号:
    10541215
  • 项目类别:
  • 资助金额:
    $59.69万
  • 财政年份:
    2022
  • 负责人:
    XANDRA OWENS BREAKEFIELD
  • 依托单位:
Gene therapy for tuberous sclerosis
  • 批准号:
    9979978
  • 项目类别:
  • 资助金额:
    $42.0万
  • 财政年份:
    2019
  • 负责人:
    XANDRA OWENS BREAKEFIELD
  • 依托单位:
Gene therapy for tuberous sclerosis
  • 批准号:
    9810206
  • 项目类别:
  • 资助金额:
    $42.0万
  • 财政年份:
    2019
  • 负责人:
    XANDRA OWENS BREAKEFIELD
  • 依托单位:
Gene therapy for Tuberous Sclerosis
  • 批准号:
    10618718
  • 项目类别:
  • 资助金额:
    $42.0万
  • 财政年份:
    2019
  • 负责人:
    XANDRA OWENS BREAKEFIELD
  • 依托单位:
海外基金